Inovio Pharmaceuticals Inc [NASDAQ: INO] jumped around 0.42 points on Wednesday, while shares priced at $2.46 at the close of the session, up 20.59%.
Inovio Pharmaceuticals Inc stock is now -67.24% down from its year-to-date (YTD) trading value. INO Stock saw the intraday high of $2.51 and lowest of $2.025 per share. The company’s 52-week high price is 7.61, which means current price is +89.23% above from all time high which was touched on 08/27/25.
Compared to the average trading volume of 2.06M shares, INO reached a trading volume of 7052350 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Inovio Pharmaceuticals Inc [INO]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for INO shares is $7.47 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on INO stock is a recommendation set at 1.67. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Piper Sandler have made an estimate for Inovio Pharmaceuticals Inc shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on July 09, 2025. While these analysts kept the previous recommendation, Stephens raised their target price to Overweight. The new note on the price target was released on May 14, 2024, representing the official price target for Inovio Pharmaceuticals Inc stock. Previously, the target price had yet another raise to $4, while Oppenheimer analysts kept a Outperform rating on INO stock.
The Price to Book ratio for the last quarter was 3.17, with the Price to Cash per share for the same quarter was set at 0.89.
How has INO stock performed recently?
Inovio Pharmaceuticals Inc [INO] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 32.97. With this latest performance, INO shares gained by 72.03% in over the last four-week period, additionally plugging by 24.24% over the last 6 months – not to mention a rise of 34.43% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for INO stock in for the last two-week period is set at 79.75, with the RSI for the last a single of trading hit 0.17, and the three-weeks RSI is set at 0.14 for Inovio Pharmaceuticals Inc [INO]. The present Moving Average for the last 50 days of trading for this stock 1.67, while it was recorded at 2.06 for the last single week of trading, and 2.18 for the last 200 days.
Inovio Pharmaceuticals Inc [INO]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Inovio Pharmaceuticals Inc [INO] shares currently have an operating margin of -52568.64% and a Gross Margin at -1560.01%. Inovio Pharmaceuticals Inc’s Net Margin is presently recorded at -48131.35%.
Inovio Pharmaceuticals Inc (INO) Capital Structure & Debt Analysis
According to recent financial data for Inovio Pharmaceuticals Inc. ( INO), the Return on Equity (ROE) stands at -140.12%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -86.88%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Inovio Pharmaceuticals Inc’s Return on Invested Capital (ROIC) is -240.23%, showcasing its effectiveness in deploying capital for earnings.
Inovio Pharmaceuticals Inc (INO) Efficiency & Liquidity Metrics
Based on Inovio Pharmaceuticals Inc’s (INO) latest financial statements, the Debt-to-Equity Ratio is 0.37%, indicating its reliance on debt financing relative to shareholder equity.
Inovio Pharmaceuticals Inc (INO) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Inovio Pharmaceuticals Inc. (INO) effectively leverages its workforce, generating an average of -$654925.37 per employee. The company’s liquidity position is robust, with a Current Ratio of 1.66% and a Quick Ratio of 1.66%, indicating strong ability to cover short-term liabilities.
Earnings analysis for Inovio Pharmaceuticals Inc [INO]
With the latest financial reports released by the company, Inovio Pharmaceuticals Inc posted -0.89/share EPS, while the average EPS was predicted by analysts to be reported at -1.13/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 0.24. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for INO. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Inovio Pharmaceuticals Inc go to 44.83%.
Insider trade positions for Inovio Pharmaceuticals Inc [INO]
There are presently around $19.04%, or 19.13%% of INO stock, in the hands of institutional investors. The top three institutional holders of INO stocks are: DEEP TRACK CAPITAL, LP with ownership of 2.07 million shares, which is approximately 7.5988%. BLACKROCK INC., holding 1.71 million shares of the stock with an approximate value of $$13.79 million in INO stocks shares; and BLACKROCK INC., currently with $$12.78 million in INO stock with ownership which is approximately 5.8151%.
